Intersect ENT Inc (NASDAQ:XENT) Investor Investigation Over Potential Securities Laws Violations Announced

If you purchased shares of Intersect ENT Inc (NASDAQ:XENT), you have certain options and you should contact the Shareholders Foundation, Inc.

To have your information reviewed for options and to recieve notifications about this investigation, please use this form. You may also send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.
Company Name(s): 
Intersect ENT
Affected Securities: 
NASDAQ: XENT

November 18, 2016 (Shareholders Foundation) - An investigation on behalf of investors of Intersect ENT Inc (NASDAQ:XENT) shares over potential securities laws violations by Intersect ENT and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Intersect ENT Inc (NASDAQ:XENT) concerning whether a series of statements regarding Intersect ENT Inc’s business, its prospects and its operations were materially false and misleading at the time they were made.

Commercial stage drug-device company Intersect ENT Inc conducted its initial public offering in July 2014. Shares of Intersect ENT Inc (NASDAQ:XENT) grew from $12.30 per share in August 2014 to as high as $32.44 per share in July 2015.

Menlo Pakr, CA based Intersect ENT Inc reported that its annual Total Revenue rose from 38.59 per million in 2014 to $61.59 million in 2015 while its Net Loss increased from $18.36 million in 2014 to $26.63 million in 2015.

On November 2, 2016, Intersect ENT Inc reported its third quarter 2016 results and updated its 2016 outlook.

Shares of Intersect ENT Inc (NASDAQ:XENT) declined on November 2, 2016 to as low as $7.65 per share.